表紙:難発現タンパク質の世界市場 (2021年~2028年)
市場調査レポート
商品コード
1020343

難発現タンパク質の世界市場 (2021年~2028年)

Global Difficult to Express Proteins Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=130.29円
難発現タンパク質の世界市場 (2021年~2028年)
出版日: 2021年07月28日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

難発現タンパク質とは、従来のin vivoタンパク質生産プラットフォームでは合成が困難なタンパク質のことです。さらに、これらのタンパク質は、その独特の性質や、凝集して封入体を形成する傾向、外来ホストがタンパク質を正しく折り畳むことが困難であることから、異種発現システムで発現させることが困難な場合が多くなっています。特殊なタンパク質の中でも、膜タンパク質や抗体タイプ、プロテアーゼ、キナーゼなどが難発現性タンパク質となっています。

当レポートでは、世界の難発現タンパク質の市場について分析し、市場規模の動向見通しや、タンパク質別・技術別・用途別・地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどについて調査しております。

目次

第1章 世界の難発現タンパク質市場:分析手法・範囲

第2章 世界の難発現タンパク質市場:市場の傾向と動静

第3章 世界の難発現タンパク質市場:エグゼクティブサマリー

第4章 世界の難発現タンパク質市場:市場力学

  • 市場への影響要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の難発現タンパク質市場:業界分析

  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析

第6章 世界の難発現タンパク質市場:新型コロナウイルス感染症 (COVID-19) の分析

  • COVID-19の市場への影響の分析
    • 「ビフォーコロナ」/過去の市場シナリオ
    • 「ウィズコロナ」/現在の市場シナリオ
    • 「アフターコロナ」/将来の市場シナリオ
  • COVID-19流行中の価格動向
  • 需要・供給の変動域
  • 感染拡大時の市場に対する政府の取り組み
  • メーカー各社の戦略展開状況

第7章 世界の難発現タンパク質市場:タンパク質別

  • イントロダクション
    • 市場規模の分析と対前年成長率 (YoY):タンパク質別
    • 市場求心力指数:タンパク質別
  • プロテアーゼ
  • キナーゼ
  • 膜タンパク質
  • その他

第8章 世界の難発現タンパク質市場:技術別

  • イントロダクション
  • 無細胞タンパク質合成
  • 原核生物の発現システム
  • SUMOフュージョンシステム
  • 遺伝子融合システム
  • その他

第9章 世界の難発現タンパク質市場:用途別

  • イントロダクション
  • 創薬
  • タンパク質精製
  • タンパク質治療
  • 疾患の診断・モニタリング
  • その他

第10章 世界の難発現タンパク質市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の難発現タンパク質市場:競合情勢

  • 競争シナリオ
  • 企業戦略の分析
  • 比較分析
  • 市場ポジショニング/シェア分析
  • 企業合併・買収 (M&A) の分析

第12章 企業プロファイル

  • Bio-Rad Laboratories
    • 企業概要
    • 製品の形状/ポートフォリオ/概略
    • 近年の動向
    • 主な財務指標
  • R&D Systems
  • Enzo Life Sciences
  • Sino Biological
  • Thermo Fisher Scientific
  • StressMarq Biosciences
  • LifeSensors
  • Lucigen
  • Origene
  • Biolegend

第13章 世界の難発現タンパク質市場:重要考察

第14章 DataM Intelligenceについて

目次
Product Code: DMHC2315

Market Overview:

Difficult-to-express proteins are the proteins whose synthesis is difficult in conventional in vivo protein production platforms. Moreover, it is often challenging to express these proteins in heterologous expression systems due to their inherent properties, tendency to aggregate and form inclusion bodies, intrinsic nature and difficultly for the foreign host to fold a protein correctly. The special type of proteins such as membrane proteins, antibody types, proteases, kinases, and others are the difficult-to-express proteins.

The Global Difficult to Express Protein Market is valued USD XX billion in 2020 and is estimated to reach USD XX billion by 2028, at a CAGR of XX%.

Market Dynamics:

The market growth is driven by the rising manufacturing of recombinant proteins for producing complex therapeutics. There is an increase in the research and development activities for the development of difficult-to-express proteins therapeutics due to their properties such as solubility, immunogenicity, and bioactivity when expressed in mammalian cells.

The market is witnessing the development of novel cell-free protein synthesis platforms based on the industrial working horse CHO cells that overcome the issues. For instance, In March 2019, Catalent had launched its next-generation cell line development technology i.e., GPEx Boost to enhance the GPEx expression platform through multiple improvements, including utilization of glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of both technology and platform enhancements would result in the cell's improved ability to produce high titers and increase specific protein productivities of interest.

In March 2019, ExcepGed launched Y Combinator with technology that uses an engineered human cell line to produce full-length human proteins for drug discovery. This platform would be used to rapidly express proteins in mammalian cells with the potential to successfully express these larger proteins.

There is an increase in the development of several techniques such as different expression systems, promoters, cultivation media and condition, chaperone coexpression, solubilization ta, gs, others for producing and purifying difficult-to-express proteins. However, the high cost of systems and difficulty in analysing target is expected to hinder the market growth.

Covid-19 Impact Analysis:

The pandemic has had a positive impact on the healthcare industry, including Difficult to Express Protein market. With Several vaccine development and drug discovery campaigns underway the protease segment is has seen a massive development. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. The ability to express and purify the proteins in large quantities is critical for basic research and for development of pharmaceutical agents. Covid-19 is expected to positively impact the SUMO fusion synthesis segment. SUMO fusion synthesis had been used in the expression and purification of SARS-CoV. fusion of SUMO to the N-termini of SARS-CoV proteins dramatically enhances expression in Escherichia coli cells.

Market Segmentation:

The difficult-to-express proteins market is segmented based on protein as proteases, kinases, membrane proteins, and others. Membrane proteins segment account for the significant market share due to the increase in usage of membrane proteins for incorporation into, or binding to, membranes. Transport proteins are essential for the movement of molecules and ions across the membrane. Peripheral membrane proteins act by binding to integral membrane proteins through compatible binding sites. Integral membrane proteins are incorporated into the hydrophobic portion of the lipid bilayer.

Protease segment is expected to have positive market growth due to rising usage of proteases for brewing, tenderization of meat, milk coagulation, digestion, viral and cancer treatment.

Further, the market is also classified based on application into technology as cell-free protein synthesis, prokaryotic expression systems, sumo fusion system, gene fusion systems, and others. Cell-free protein synthesis accounts for the significant market share owing to its advantages in synthesizing difficult-to-express proteins because of its properties such as reaction environment openness and no cell viability constraints. It maximizes active protein production by optimizing the reaction environment with selective positive effectors and eliminating negative effectors.

Prokaryotic expression systems segment accounts for the significant market as it provides a cost-effective, tuneable, and easy to operate a source of recombinant proteins. Companies are introducing new approaches for the production of complex eukaryotic proteins in a prokaryotic expression.

Geographical Penetration:

By region, the difficult-to-express proteins market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East and Africa. Among all of the regions, the North America region dominated the difficult-to-express proteins market due to increasing research and development activities for the development of different technologies for the synthesis of difficult-to-express proteins. Several companies are entering into the collaborations with the other companies, organizations, and institutes for developing the products related to difficult-to-express proteins. It is further expected that the North America region would maintain its dominant position over the forecasted period.

Europe is expected to have a significant market share owing to the increasing investment from the government and non-government organizations. The growing prevalence of chronic disease shall stimulate market growth. Chronic diseases are the leading cause of mortality and morbidity in European Countries. The burden of developing chronic diseases such as cardiovascular disease, diabetes, asthma, chronic obstructive pulmonary disease (COPD), HIV/AIDS, mental disorder, and others increases aging populations. According to Eurostat, age-group of aged 65 and more accounts for one-fifth, i.e., 19 % of the European population.

Asia Pacific region is expected to have positive market growth due to increasing the number of several pharmaceutical and biotechnology companies developing therapeutics and technologies related to difficult-to-express proteins. There is an increase in the adoption of novel technologies for the synthesis of difficult-to-express proteins. The rising awareness regarding the novel technologies shall stimulate market growth over the forecasted period.

Competitive Landscape:

The difficult-to-express proteins market is highly competitive with the product diversification, revenue generation, and opportunities. Several local and international players are present in the market. R&D Systems, Bio-Rad Laboratories, Enzo Life Sciences, Sino Biological, Thermo Fisher Scientific, StressMarq Biosciences, and Lucigen are the leading market players with significant market share.

Companies are focusing on new product launches, technological advancement, product diversification, market expansion, and market penetration strategies for strengthening their position in the market. They are conducting research and development activities for developing difficult-to-express proteins with innovation and diversification. For instance, In May 2019, Catalent had launched its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologics. One Bio would help in addressing the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework.

The companies are entering into the collaborations, mergers, licensing agreements, strategic partnerships and acquisitions to increase the demand for difficult-to-express proteins and their expansion across the globe. For instance, in April 2019, Calixar had entered into the exclusive licensing deal with Regeneron. Calyx had provided Regeneron exclusive rights to its technology and expertise. Calixar's technology platform would allow the company to isolate the full length and pure to highly pure membrane proteins while keeping their structure and function intact. The types of membrane proteins include GPCRs, ion channels, transporters, receptors, and viral proteins.

Lonza America had acquired exclusive rights to Transposagen's proprietary gene integration technology for the production of therapeutic proteins. Transposagen's gene integration technology would enable the efficient production of high-titer cell lines that provides the rapid and economical production of complex biological molecules. In September 2017, Airway Therapeutics entered into an exclusive licensing agreement with Glycotope GmbH [Glycotope]. Under the terms of this agreement, Airway had received the worldwide commercial rights to use Glycotope's proprietary cell line technology, GlycoExpress [GEX], to produce AT-100 (rhSP-D). The GlycoExpress would accelerate the development and large-scale manufacturing of a wide range of biologics, including antibodies and difficult-to-express proteins.

Companies are also raising the funding and investment for increasing their market presence across the globe. For instance, in March 2019, Algenex had raised the funding of Euros 4 million for the production of the recombinant biologics. The company would use the scale-up its proprietary CrisBio baculovirus-expression platform ahead of an anticipated submission to the European Medicines Agency (EMA) of a CrisBio-based minor species vaccine. It would further the commercial rollout of its TopBac system, a plug and play patented technology that increases existing baculovirus systems' productivities.

Bio-Rad Laboratories:

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets established in 1952. Bio-Rad has a worldwide presence with more than 8000 employees and direct channels in 35 different countries outside U.S.

Product Portfolio of Bio-Rad Laboratories:

  • Digital Biology
  • Genomics
  • Quality Controls
  • Clinical Diagnostics
  • Protein Quantitation and Purification
  • Cell Biology
  • Food Safety
  • Science Education

Key Developments:

  • InApril 2020, Bio-Rad announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Celsee's Genesis System offers a practical, scalable, and efficient approach to accurately analyze single cells.
  • In November 2019, The ProteinChip SELDI system starter kit has been redesigned to deliver a step-by-step focused introduction to ProteinChip SELDI technology. The kit is a training tool that includes a video tutorial and the ProteinChip arrays, buffer, and reagents needed to generate and evaluate protein profiles from the included human serum and E. coli samples.

Why Purchase the Report:

  • Visualize the composition of the Difficult-to-Express Proteins market products across each indication, highlighting the critical commercial assets and play in terms of technology and applications.
  • Identify commercial opportunities in the Difficult-to-Express Proteins market by analysing trends and co-development deals.
  • Excel data sheet with thousands of data points of Difficult-to-Express Proteins market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The Difficult-to-Express Proteins report will provide access to approximately 53 market data tables, 44 figures, and 178 pages

Target Audience:

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Table of Contents

1. Global Difficult to Express Protein Market -Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Global Difficult to Express Protein Market -Key Trends and Developments

3. Global Difficult to Express Protein Market - Executive Summary

  • 3.1. Market Snippet by Protein
  • 3.2. Market Snippet by Technology
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Global Difficult to Express Protein Market - Market Dynamics

  • 4.1. Market impacting factors
  • 4.2. Drivers
  • 4.3. Restraints
  • 4.4. Opportunities
  • 4.5. Impact analysis

5. Global Difficult to Express Protein Market - Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Pricing analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis

6. Global Difficult to Express Protein Market - Covid-19 Impact Analysis

  • 6.1. Porter's five forces analysis
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. Global Difficult to Express Protein Market - By Protein

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein
    • 7.1.2. Market Attractiveness Index, By Protein
  • 7.2. Proteases
  • 7.3. Kinases
  • 7.4. Membrane Proteins
  • 7.5. Others

8. Global Difficult to Express Protein Market - By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Cell-free Protein Synthesis
  • 8.3. Prokaryotic Expression Systems
  • 8.4. SUMO Fusion System
  • 8.5. Gene Fusion Systems
  • 8.6. Others

9. Global Difficult to Express Protein Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Drug Discovery
  • 9.3. Protein Purification
  • 9.4. Protein Therapeutics
  • 9.5. Disease Diagnostics and Monitoring
  • 9.6. Others

10. Global Difficult to Express Protein Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Chile
      • 10.4.7.4. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia & New Zealand
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. The Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
    • 10.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User

11. Global Difficult to Express Protein Market - Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Comparative analysis
  • 11.4. Market positioning/share analysis
  • 11.5. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories
    • 12.1.1. Company Overview
    • 12.1.2. Form Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. R&D Systems
  • 12.3. Enzo Life Sciences
  • 12.4. Sino Biological
  • 12.5. Thermo Fisher Scientific
  • 12.6. StressMarq Biosciences
  • 12.7. LifeSensors
  • 12.8. Lucigen
  • 12.9. Origene
  • 12.10. Biolegend

13. Global Difficult to Express Protein Market - Premium Insights

14. Global Difficult to Express Protein Market - DataM

  • 14.1. Appendix
  • 14.2. About us and services
  • 14.3. Contact us